Harrow (NASDAQ:HROW) Trading Up 5.7% - Time to Buy?

Shares of Harrow, Inc. (NASDAQ:HROW - Get Free Report) rose 5.7% during trading on Monday . The stock traded as high as $37.27 and last traded at $36.91. Approximately 192,886 shares changed hands during mid-day trading, a decline of 61% from the average daily volume of 496,404 shares. The stock had previously closed at $34.93.

Analyst Ratings Changes

Several research firms have recently issued reports on HROW. HC Wainwright boosted their price target on shares of Harrow from $57.00 to $60.00 and gave the company a "buy" rating in a research report on Monday, May 12th. B. Riley lowered their price target on shares of Harrow from $69.00 to $65.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. William Blair began coverage on shares of Harrow in a research report on Tuesday, June 10th. They issued an "outperform" rating on the stock. Cantor Fitzgerald began coverage on shares of Harrow in a research report on Friday, July 11th. They issued an "overweight" rating and a $76.00 price target on the stock. Finally, BTIG Research began coverage on shares of Harrow in a research note on Thursday, June 12th. They set a "buy" rating and a $62.00 price objective for the company. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Harrow presently has a consensus rating of "Buy" and a consensus target price of $63.83.

Harrow Stock Up 4.6%

The company has a market cap of $1.33 billion, a PE ratio of -64.53 and a beta of 0.41. The stock's 50 day moving average price is $29.65 and its 200-day moving average price is $28.84. The company has a debt-to-equity ratio of 2.01, a quick ratio of 0.85 and a current ratio of 0.91.

Harrow (NASDAQ:HROW - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). The company had revenue of $47.83 million during the quarter, compared to the consensus estimate of $57.00 million. Harrow had a negative return on equity of 25.01% and a negative net margin of 10.19%. On average, analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current year.

Hedge Funds Weigh In On Harrow

A number of institutional investors and hedge funds have recently made changes to their positions in the business. GF Fund Management CO. LTD. purchased a new position in Harrow during the fourth quarter valued at approximately $25,000. Quarry LP purchased a new position in Harrow during the first quarter valued at approximately $32,000. Tower Research Capital LLC TRC lifted its holdings in Harrow by 769.5% during the fourth quarter. Tower Research Capital LLC TRC now owns 1,652 shares of the company's stock valued at $55,000 after purchasing an additional 1,462 shares in the last quarter. Aquatic Capital Management LLC purchased a new position in Harrow during the fourth quarter valued at approximately $78,000. Finally, State of Wyoming purchased a new position in Harrow during the first quarter valued at approximately $97,000. Hedge funds and other institutional investors own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.